Unregulated peptides: what the science actually says

The surge in popularity of peptides within the wellness community raises a fundamental question: what do we actually know about their safety and efficacy? In this conversation, a scientist who works in preclinical drug development explains, from the inside of the process, why the enthusiasm around compounds like BPC-157, TB-500, or CJC does not match the scientific evidence being attributed to them.

Three categories of peptides: they are not the same

It is worth separating three very different groups before discussing risk:

• FDA-approved peptides: such as GLP-1 receptor agonists (semaglutide, tirzepatide) or insulin. They have gone through decades of development, phase 1, 2, and 3 clinical trials, and have an established risk-benefit profile.
• Gray-market copies: compounded versions of those same approved peptides, distributed without the controls that apply to the original drugs.
• Research-use-only peptides: compounds like BPC-157, TB-500, CJC-1295, or ipamorelin. They lack robust human clinical data, have not completed the drug development process, and are sold under the legal label "for research use only."

The development process these peptides have not completed

Developing a drug takes 10 to 15 years, and more than 99% of ideas fail somewhere along the way. The basic steps include molecular characterization of the therapeutic target, establishing a pharmacokinetic-pharmacodynamic (PKPD) relationship in animal models, preclinical safety and toxicology studies in rodents and non-rodents, and clinical phases 1, 2, and 3 in humans.

Research-use-only peptides have completed virtually none of these steps. It is not known precisely which receptors they bind in humans, how they affect cellular pathways in vivo, what the safe dose is, or what the therapeutic index looks like. Available data come almost exclusively from cell or rodent studies, in many cases from a small number of research groups without broad scientific replication.

Why "natural" does not mean "safe"

A common argument is that these peptides are "natural" because the body produces similar molecules. This is what is known as the appeal-to-nature fallacy. BPC-157, for example, is a fragment of a larger peptide that the body does produce, but that specific fragment with that exact sequence is not generated endogenously. The same applies to TB-500, a fragment of thymosin beta-4.

Additionally, many of the pathways these compounds appear to activate, such as cell proliferation and angiogenesis (blood vessel formation), are the same pathways found dysregulated in certain cancers. This does not mean the peptides cause cancer, but it does mean that someone with an unknown predisposition could be accelerating a pathological process without knowing it.

The problem of sourcing and contamination

Research-use-only peptides are often obtained through unregulated channels, with no guarantees of purity or sterility. Severe infections caused by Mycobacterium abscessus, a bacterium related to tuberculosis, have been documented in people injecting peptides intramuscularly. These infections are extremely difficult to treat.

The regulatory reclassification in the United States that has generated recent headlines does not amount to FDA approval and does not indicate that new clinical trial data exist. What changes is that compounding pharmacies may prepare these compounds with better quality control for specific medical indications; no new evidence has been generated about their efficacy or safety for general use.

A pro-evidence position, not an anti-peptide one

The scientist's position is not against peptides in the abstract but in favor of evidence. If clinical data eventually demonstrate efficacy and safety, these compounds will deserve serious consideration. The problem is that those data do not yet exist for most of these molecules.

Anyone who decides to use them is accepting an unknown risk. Unlike approved GLP-1s, where the most common adverse effects and therapeutic margins are established, with research-use-only peptides it is not known what can go wrong, at what dose, or over what timeframe. For anyone who wants to check whether a compound is being studied in humans, clinicaltrials.gov is a public resource where all authorized clinical trials are registered.

Conclusion

Enthusiasm is not a substitute for data. Research-use-only peptides may turn out to be safe and effective, but the scientific community does not yet have the information needed to know that. Before injecting any unapproved compound, it is worth understanding what development process that compound has not completed.